conatumumab conatumumab conatumumab (originally amg-655) is a monoclonal antibody developed for the treatment of cancer. it is a fully human monoclonal agonist antibody directed against the extracellular domain of human trail (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (tr-2, death receptor 5) with potential antineoplastic activity. conatumumab mimics the activity of native trail, binding to and activating tr-2, thereby activating caspase cascades and inducing tumor cell apoptosis. tr-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin. conatumumabmonoclonal antibodytypewhole antibodysourcehumantargettrail-r2 (cd262)clinical dataother namesanti-trail receptor 2 monoclonal antibody, amg-655atc codenoneidentifierscas number896731-82-1 nchemspidernoneunii1p48l61km0keggd09329 ychemical and physical dataformulac6466h10006n1730o2024s40molar mass145645.66 g·mol−1 ny (what is this?) (verify) the drug was developed by amgen inc. in 2008, takeda licensed the drug from amgen for development in japan, but discontinued development in 2011.